Baxter to Acquire Seprafilm Adhesion Barriers from Sanofi for $350M
Baxter’s Eptifibatide Receives the US FDA’s Approval for Cardiovascular Diseases
Shots:
- Baxter signs an agreement with Sanofi to acquire Seprafilm Adhesion Barrier and related assets for $350M with expected closure of transaction in Q1’20
- The focus of the acquisition to expand Baxter’s advanced surgery portfolio that accompany the portfolio of hemostat and sealant across the hospital, including in the operating room
- Seprafilm Adhesion Barrier is targeted for undergoing abdominal or pelvic laparotomy for reducing the incidence, extent and severity of postoperative adhesions between the abdominal wall and the underlying viscera and is marketed in the US, Japan, China, South Korea and France
Click here to read full press release/ article | Ref: Baxter | Image: Twitter